The Phase I ADC trial will evaluate the safety and efficacy of the company’s drug which targets tumours whilst leaving normal ...
Novo Nordisk has reported topline outcomes from a Phase Ib/IIa trial of amycretin designed for treating obese or overweight ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback